Clinical trial • Phase I • Dermatology

EGL-003 for Atopic dermatitis

Phase I trial of EGL-003 for Atopic dermatitis. open-label, adaptive. 58 participants.

Overview

Trial Therapeutic Area
Dermatology
Trial Disease
Atopic dermatitis
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
26-06-2025
First CTIS Authorization Date
01-10-2025

Trial design

open-label, adaptive Phase I trial across 12 sites in Germany, Bulgaria, Poland.

Open Label
Yes
Adaptive
Yes
Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
58

Eligibility

Recruits 58 Vulnerable population not selected; participants are adults (healthy volunteers and adults with autoimmune disease); no special consent or assent handling described in the record..

Vulnerable Population
Vulnerable population not selected; participants are adults (healthy volunteers and adults with autoimmune disease); no special consent or assent handling described in the record.

Recruitment

Planned Sample Size
58
Recruitment Window Months
12
Consent Approach
Informed consent to be provided by adult participants; no assent or paediatric consent described; specific consent language(s) or materials not specified.

Geography

Total Number Of Sites
12
Total Number Of Participants
58

Germany

Earliest CTIS Part Ii Submission Date
08-09-2025
Latest Decision Or Authorization Date
29-01-2026
Processing Time Days
143
Number Of Sites
5
Number Of Participants
40

Sites

Site Name
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Department Name
Dermatology
Contact Person Name
Stefan Beissert
Contact Person Email
Stefan.beissert@ukdd.de
Site Name
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Department Name
Dermatology
Contact Person Name
Caroline Mann
Site Name
Universitaetsklinikum Tuebingen AöR
Department Name
Dermatology
Contact Person Name
Sebastian Volc
Site Name
Universitaetsklinikum Schleswig-Holstein AöR
Department Name
Dermatology, Venereology and Allergology
Contact Person Name
Dora Stoelzl
Site Name
DRK Kliniken Berlin
Department Name
Early Phase Clinical Unit (EPCU) Berlin
Contact Person Name
Dirk Palla
Contact Person Email
dirk.palla@parexel.com

Bulgaria

Earliest CTIS Part Ii Submission Date
08-09-2025
Latest Decision Or Authorization Date
02-02-2026
Processing Time Days
147
Number Of Sites
4
Number Of Participants
10

Sites

Site Name
Medical Center Etika Ambulatory For Specialized Outpatient Medical Care OOD
Department Name
Not applicable
Contact Person Name
Boyan Kostov
Contact Person Email
kostov.derma@abv.bg
Site Name
Medical Center Medconsult Pleven OOD
Department Name
Dermatology
Contact Person Name
Krasimira Vasileva
Contact Person Email
vasileva_mclovech@abv.bg
Site Name
Medical Center Excelsior OOD
Department Name
Not applicable
Contact Person Name
Todor Popov
Contact Person Email
ted.popov@gmail.com
Site Name
Medical Center Medconsult Pleven OOD
Department Name
Dermatology
Contact Person Name
Kamelia Vekovska
Contact Person Email
kvekovska_medconsult@abv.bg

Poland

Earliest CTIS Part Ii Submission Date
08-09-2025
Latest Decision Or Authorization Date
02-02-2026
Processing Time Days
147
Number Of Sites
3
Number Of Participants
8

Sites

Site Name
Dermedic Jacek Zdybski
Department Name
Dermatology
Contact Person Name
Jacek Zdybski
Contact Person Email
jacek@zdybski.pl
Site Name
Labderm Essence Sp. z o.o.
Department Name
Dermatology
Contact Person Name
Beata Bergler-Czop
Contact Person Email
bbergler-czop@sum.edu.pl
Site Name
Dermaceum Sp. z o.o.
Department Name
DERMACEUM Centrum Medyczne
Contact Person Name
Michal Torz
Contact Person Email
m.torz@dermaceum.pl

Sponsor

Primary sponsor

Full Name
Egle Therapeutics
Organisation Type
Pharmaceutical company
Country Of Registered Address
France

Investigational products

Investigational Product Name
EGL-003
First In Human
Yes

Related trials

Other published trials that may interest you.